Skip to main content
Premium Trial:

Request an Annual Quote

BD to Seek $1B Loan Facility; Expects to Incur Less Debt for CareFusion Acquisition

NEW YORK (GenomeWeb) – Becton Dickinson today disclosed in a filing with the US Securities and Exchange Commission that it expects to seek commitments for a new, 364-day $1 billion term loan facility, which it expects to use to partly fund its $12.2 billion acquisition of CareFusion.

Two weeks ago, BD said that it had entered into a $9.1 bridge loan agreement to help fund the acquisition. But today the firm said that it now expects to use a greater portion of its cash on hand to fund the cash consideration of the deal. As a result, it expects to incur roughly $7.7 billion in debt connected to the acquisition, which includes the term loan facility, rather than the previously announced $9.1 billion.

With the lower amount of debt, BD now expects the CareFusion acquisition to be accretive to its earnings per share on a high-teen percentage basis in the first full year following completion of the deal.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.